This initiative involves a multilevel review process, including pathologists and tumor registrars, of standards for tumor site-morphology combinations, terminology, and coding. The updated standards (valid, unlikely, and impossible) for the 2024 (V2024A) and 2025 (V2025A) and standards for 2026 (V2026) Cancer PathCHART ICD-O-3 Site Morphology Validation List are freely available to cancer registration software vendors and any other end users in easily consumed, computer-readable formats (e.g., XLSX, CSV, XML, JSON) on the Product Downloads page. The latest version of standards from 2024 to 2026 are in one CPC SMVL file (version V2024A_V2025A_V2026).

Review Process
review process

The aim of this multilevel review process is to assign one of the Cancer PathCHART (CPC) designations: Valid, Unlikely, or Impossible, to all site-morphology combinations.

The first review is by a SEER*ClinCORE subspecialty pathologist. The second level of independent review is performed in parallel by 2 to 3 subject matter expert pathologists. Any discrepancies in designations are resolved in a consensus meeting where pathologists and cancer registrars participate.

The following cancer registrars' review focuses on discovering potential conflicts between the CPC designations and other sources used by cancer registrars. Discrepancies are resolved in a consensus meeting with cancer registrars and the SEER*ClinCORE pathologist.